Skip to main content
Figure 6 | BMC Cancer

Figure 6

From: Targeting connexin 43 with α–connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1

Figure 6

Proliferation and apoptosis are differentially altered by ACT1 in MCF7 and BT474 breast cancer cell lines. (A) Whole cell extracts isolated from MCF10A, MCF7, BT474, and MDA MB 231 cells were immunoblotted for Cx43 and ZO-1. (B) The ratio of Cx43 to ZO-1 expression was evaluated using the Odyssey imaging system. Cx43 and ZO-1 levels were normalized to β-tubulin expression. (C) MCF7 and BT474 cells were treated for 24 hours with R-pep (200 μM), ACT1 (200 μM), ACT1 plus Tamoxifen-MCF7, or ACT1 plus Lapatinib-BT474 and then analyzed for cleaved-PARP (cl-PARP) expression. (D) MCF10A and BT474 lysates treated with R-pep (200 μM) or ACT1(200 μM) were immunoblotted for cl-PARP and cleaved-Caspase-3 (cl-Caspase-3).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us